Australia markets closed

Soleno Therapeutics, Inc. (SLNO)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
37.88+0.54 (+1.46%)
As of 01:05PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close37.34
Open37.09
Bid37.86 x 100
Ask38.08 x 100
Day's range37.09 - 37.95
52-week range3.19 - 53.82
Volume35,026
Avg. volume312,095
Market cap1.266B
Beta (5Y monthly)-1.54
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    REDWOOD CITY, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced, as required by Nasdaq Stock Market rules, the grant of inducement awards to six new employees. The independent members of the Board of Directors of Soleno approved the grant of non-qualified stock options to purchase 96,500 shares of common stock to six employees

  • GlobeNewswire

    Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results

    REDWOOD CITY, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the fourth quarter and full-year ended December 31, 2023. Full Year 2023 and Recent Corporate Highlights Announced positive statistically significant top-line data from the randomized withdrawal period of Study C6

  • GlobeNewswire

    Soleno Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

    REDWOOD CITY, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present at the TD Cowen 44th Annual Healthcare Conference on Monday, March 4, 2024, at 1:30 PM Eastern Time. A live audio webcast and replay of the presentation will be available in the Investors section on t